Page 243 of 449: studies 2,421 to 2,430 of 4,483, newest first. Back to the ketamine overview
Archives of Psychiatry and Behavioral Sciences 2019 Michael Hart, Zack Z. Cernovsky 1 citation
present study extends the application of ketamine to patients with history of not only chronic
Journal of Affective Disorders 2019 Dawn F. Ionescu, Kate H Bentley, M. Eikermann et al. 179 citations
BACKGROUND Several studies indicate that ketamine has rapid antidepressant effects in patients with treatment-resistant depression (TRD). The extent to which repeated doses of ketamine (versus placebo) reduce depression in the short and long term among outpatients with TRD and chronic, current suicidal ideation remains unknown. METHODS Twenty-six medicated outpatients with severe major...
Indian Journal of Psychiatry 2019 Suprio Mandal, VinodKumar Sinha, Nishant Goyal 92 citations
BACKGROUND: Severe depressive disorder is among most debilitating condition. Conventional pharmacotherapy usually takes several weeks (usually 4-12 weeks) to improve symptoms. Ketamine is an N-methyl-D aspartate receptor antagonist having rapid action on depressive symptoms. OBJECTIVES: The effect of subanesthetic dose of ketamine was assessed on depressive and anxiety symptoms. Illness...
Depression and Anxiety December 30, 2018 Naji C. Salloum, Maurizio Fava, Marlene P. Freeman et al. 49 citations
OBJECTIVE: To examine the effect of high baseline anxiety on response to ketamine versus midazolam (active placebo) in treatment-resistant depression (TRD). METHODS: In a multisite, double-blind, placebo-controlled trial, 99 subjects with TRD were randomized to one of five arms: a single dose of intravenous ketamine 0.1, 0.2, 0.5, 1.0 mg/kg, or midazolam 0.045 mg/kg. The primary outcome measure...
Proceedings of the National Academy of Sciences December 17, 2018 Kenichi Fukumoto, Manoela V. Fogaça, Rong-Jian Liu et al. 191 citations
Significance A metabolite of ketamine, (2 R ,6 R )-hydroxynorketamine [(2 R ,6 R )-HNK], produces rapid and sustained antidepressant effects in animal models but without the side effects of ketamine. Notably, (2 R ,6 R )-HNK does not block the NMDA receptor, the primary target of ketamine. Here, we demonstrate that the antidepressant effects of (2 R ,6 R )-HNK require activity dependent release...
December 7, 2018
Ketamine (an NMDA antagonist) is associated with a fast but transient antidepressant response in treatment-resistant patients Ketamine forms that are safer and able to overcome the transient effect limitation are being studied in clinical trials Ketamine’s mechanism of action could be linked to the metabolite hydroxynorketamine and its activity on glutamate AMPA receptors
Expert Review of Neurotherapeutics December 4, 2018 Kai Zhang, Kenji Hashimoto 133 citations
Introduction: Depression is one of the most disabling diseases worldwide. Approximately one-third of depressed patients are treatment-resistant to the currently available antidepressants and there is a significant therapeutic time lag of weeks to months. There is a clear unmet need for rapid-acting and more efficacious treatments. (R,S)-ketamine, an old anesthetic drug, appears now to be going...
Psychopharmacology December 2018 M Steffens, Claudia Neumann, A-M Kasparbauer et al.
The uncompetitive N-methyl-D-aspartate (NMDA) receptor (NMDAR) antagonist ketamine has been proposed to model symptoms of psychosis. Inhibitory deficits in the schizophrenia spectrum have been reliably reported using the antisaccade task. Interestingly, although similar antisaccade deficits have been reported following ketamine in non-human primates, ketamine-induced deficits have not been...
Pharmacology, Biochemistry, and Behavior December 2018 Zhongwei Xiong, Kai Zhang, Tamaki Ishima et al.
The negative allosteric modulators (NAMs: L-655,708 and MRK-016) of α5 subunit-containing GABAA receptors are reported to show rapid-acting antidepressant effects in rodents. However, there are no reports comparing these NAMs and (R)‑ketamine, (R)-enantiomer of the rapid-acting antidepressant ketamine, in a chronic social defeat stress (CSDS) model. Here we measured expression of α5 GABAA...
The American Journal of Medicine December 2018 Jabril Eldufani, Alireza Nekoui, Gilbert Blaise
Ketamine is considered a dissociative anesthetic medication, and it is commonly administered by a parenteral route. It works mainly by blocking the N-methyl-D-aspartate receptor. It inhibits the voltage-gated Na and K channels and serotonin and dopamine reuptake; also, it affects specific receptors, such as α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, kainate, and aminobutyric acid A...